ARTICLE | Clinical News
Cenderitide: Completed Phase II enrollment
April 13, 2015 7:00 AM UTC
Capricor completed enrollment of 14 patients in an open-label, dose-escalation, U.S. Phase II trial evaluating 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous, subcutaneous infusio...